As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves

ByHeart said independent laboratory tests confirmed Clostridium botulinum in some samples of its infant formula after an outbreak that has hospitalized 31 babies in 15 states (ages roughly 2 weeks–6 months) though no deaths have been reported; the company notified the FDA. State investigators report finding recalled product still for sale in multiple jurisdictions despite a nationwide recall, and FDA inspections of ByHeart plants in Iowa and Oregon have been conducted with results pending. Health officials are urging consumers to stop using and retain product for testing, a California hotline has been established, and the incident creates immediate public-health, regulatory and potential legal risk for ByHeart while also highlighting supply and retail-distribution implications given the company’s monthly output and major retail presence.

Analysis

An independent food-safety laboratory confirmed Clostridium botulinum in some ByHeart infant formula samples, and federal health officials say 31 babies in 15 states (ages ~2 weeks to ~6 months) have been hospitalized since August with the most recent case reported Nov. 13; ByHeart notified the FDA but has not disclosed how many samples were tested or how many were positive. State investigators report recalled ByHeart product remains on store shelves in multiple jurisdictions despite a nationwide recall — Oregon found the formula in 9 of >150 stores checked and Minnesota removed product at 4 of 119 checks — while FDA inspectors have conducted plant visits in Allerton, Iowa and Portland, Oregon with results pending. ByHeart had been producing roughly 200,000 cans per month and sold through online channels and major retailers including Target and Walmart; Walmart reports it removed product, restricted sales and is offering refunds on cans that sold for about $42. The situation creates immediate regulatory, legal and reputational risk that could translate into recall-related costs, inventory write-downs and lost future sales for ByHeart or any financially exposed partners, and public-health guidance to retain product for testing may prolong the remediation timeline and associated liabilities.

Key Decisions for Investors

• Monitor FDA inspection reports and any disclosures from ByHeart or independent labs about sample counts and positive results, as these will determine the scope of regulatory action and liability
• For investors in retailers cited (Target, Walmart), expect limited near-term disruption given swift product removal but watch for recall-related charge disclosures, refund volumes and commentary on baby-formula shelf-share in upcoming earnings updates
• Avoid initiating new exposure to firms with direct commercial or financial ties to ByHeart until the contamination scope, recall costs and potential litigation are quantified
• Prepare to reduce or hedge positions in specialty infant-formula distribution or small-cap suppliers if reporting reveals broader contamination, extended remediation or material legal settlements